Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels

S. Schedin-Weiss, M. Inoue, L. Hromadkova, Y. Teranishi, NG. Yamamoto, B. Wiehager, N. Bogdanovic, B. Winblad, A. Sandebring-Matton, S. Frykman, LO. Tjernberg,

. 2017 ; 9 (1) : 57. [pub] 20170801

Language English Country England, Great Britain

Document type Journal Article

BACKGROUND: Increased levels of the pathogenic amyloid β-peptide (Aβ), released from its precursor by the transmembrane protease γ-secretase, are found in Alzheimer disease (AD) brains. Interestingly, monoamine oxidase B (MAO-B) activity is also increased in AD brain, but its role in AD pathogenesis is not known. Recent neuroimaging studies have shown that the increased MAO-B expression in AD brain starts several years before the onset of the disease. Here, we show a potential connection between MAO-B, γ-secretase and Aβ in neurons. METHODS: MAO-B immunohistochemistry was performed on postmortem human brain. Affinity purification of γ-secretase followed by mass spectrometry was used for unbiased identification of γ-secretase-associated proteins. The association of MAO-B with γ-secretase was studied by coimmunoprecipitation from brain homogenate, and by in-situ proximity ligation assay (PLA) in neurons as well as mouse and human brain sections. The effect of MAO-B on Aβ production and Notch processing in cell cultures was analyzed by siRNA silencing or overexpression experiments followed by ELISA, western blot or FRET analysis. Methodology for measuring relative intraneuronal MAO-B and Aβ42 levels in single cells was developed by combining immunocytochemistry and confocal microscopy with quantitative image analysis. RESULTS: Immunohistochemistry revealed MAO-B staining in neurons in the frontal cortex, hippocampus CA1 and entorhinal cortex in postmortem human brain. Interestingly, the neuronal staining intensity was higher in AD brain than in control brain in these regions. Mass spectrometric data from affinity purified γ-secretase suggested that MAO-B is a γ-secretase-associated protein, which was confirmed by immunoprecipitation and PLA, and a neuronal location of the interaction was shown. Strikingly, intraneuronal Aβ42 levels correlated with MAO-B levels, and siRNA silencing of MAO-B resulted in significantly reduced levels of intraneuronal Aβ42. Furthermore, overexpression of MAO-B enhanced Aβ production. CONCLUSIONS: This study shows that MAO-B levels are increased not only in astrocytes but also in pyramidal neurons in AD brain. The study also suggests that MAO-B regulates Aβ production in neurons via γ-secretase and thereby provides a key to understanding the relationship between MAO-B and AD pathogenesis. Potentially, the γ-secretase/MAO-B association may be a target for reducing Aβ levels using protein-protein interaction breakers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024770
003      
CZ-PrNML
005      
20180712091901.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13195-017-0279-1 $2 doi
035    __
$a (PubMed)28764767
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schedin-Weiss, Sophia $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden. sophia.schedin.weiss@ki.se.
245    10
$a Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels / $c S. Schedin-Weiss, M. Inoue, L. Hromadkova, Y. Teranishi, NG. Yamamoto, B. Wiehager, N. Bogdanovic, B. Winblad, A. Sandebring-Matton, S. Frykman, LO. Tjernberg,
520    9_
$a BACKGROUND: Increased levels of the pathogenic amyloid β-peptide (Aβ), released from its precursor by the transmembrane protease γ-secretase, are found in Alzheimer disease (AD) brains. Interestingly, monoamine oxidase B (MAO-B) activity is also increased in AD brain, but its role in AD pathogenesis is not known. Recent neuroimaging studies have shown that the increased MAO-B expression in AD brain starts several years before the onset of the disease. Here, we show a potential connection between MAO-B, γ-secretase and Aβ in neurons. METHODS: MAO-B immunohistochemistry was performed on postmortem human brain. Affinity purification of γ-secretase followed by mass spectrometry was used for unbiased identification of γ-secretase-associated proteins. The association of MAO-B with γ-secretase was studied by coimmunoprecipitation from brain homogenate, and by in-situ proximity ligation assay (PLA) in neurons as well as mouse and human brain sections. The effect of MAO-B on Aβ production and Notch processing in cell cultures was analyzed by siRNA silencing or overexpression experiments followed by ELISA, western blot or FRET analysis. Methodology for measuring relative intraneuronal MAO-B and Aβ42 levels in single cells was developed by combining immunocytochemistry and confocal microscopy with quantitative image analysis. RESULTS: Immunohistochemistry revealed MAO-B staining in neurons in the frontal cortex, hippocampus CA1 and entorhinal cortex in postmortem human brain. Interestingly, the neuronal staining intensity was higher in AD brain than in control brain in these regions. Mass spectrometric data from affinity purified γ-secretase suggested that MAO-B is a γ-secretase-associated protein, which was confirmed by immunoprecipitation and PLA, and a neuronal location of the interaction was shown. Strikingly, intraneuronal Aβ42 levels correlated with MAO-B levels, and siRNA silencing of MAO-B resulted in significantly reduced levels of intraneuronal Aβ42. Furthermore, overexpression of MAO-B enhanced Aβ production. CONCLUSIONS: This study shows that MAO-B levels are increased not only in astrocytes but also in pyramidal neurons in AD brain. The study also suggests that MAO-B regulates Aβ production in neurons via γ-secretase and thereby provides a key to understanding the relationship between MAO-B and AD pathogenesis. Potentially, the γ-secretase/MAO-B association may be a target for reducing Aβ levels using protein-protein interaction breakers.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a Alzheimerova nemoc $x metabolismus $x patologie $7 D000544
650    _2
$a sekretasy $x metabolismus $7 D053829
650    _2
$a amyloidní beta-protein $x metabolismus $7 D016229
650    _2
$a zvířata $7 D000818
650    _2
$a axony $x metabolismus $7 D001369
650    _2
$a mozek $x metabolismus $x patologie $7 D001921
650    _2
$a transformované buněčné linie $7 D002461
650    _2
$a dendrity $x metabolismus $7 D003712
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese $x genetika $7 D005786
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a lidé středního věku $7 D008875
650    _2
$a molekulární modely $7 D008958
650    _2
$a monoaminoxidasa $x genetika $x metabolismus $7 D008995
650    _2
$a neurony $x metabolismus $x ultrastruktura $7 D009474
650    _2
$a presenilin-1 $x genetika $7 D053764
650    _2
$a malá interferující RNA $x genetika $x metabolismus $7 D034741
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a receptory N-methyl-D-aspartátu $x metabolismus $7 D016194
650    _2
$a synapse $x metabolismus $7 D013569
650    _2
$a transfekce $7 D014162
655    _2
$a časopisecké články $7 D016428
700    1_
$a Inoue, Mitsuhiro $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden. Present address: Dainippon Sumitomo Pharma Co., Ltd, Drug Development Research Laboratories, Osaka, Japan.
700    1_
$a Hromadkova, Lenka $u National Institute of Mental Health, Klecany, Czech Republic. Faculty of Science, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Teranishi, Yasuhiro $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden. Present address: Dainippon Sumitomo Pharma Co., Ltd, Drug Development Research Laboratories, Osaka, Japan.
700    1_
$a Yamamoto, Natsuko Goto $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden. Present address: Dainippon Sumitomo Pharma Co., Ltd, Drug Development Research Laboratories, Osaka, Japan.
700    1_
$a Wiehager, Birgitta $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden.
700    1_
$a Bogdanovic, Nenad $u Department of Geriatric Medicine, University in Oslo, Memory Clinic, Oslo University Hospital, Oslo, Norway.
700    1_
$a Winblad, Bengt $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden.
700    1_
$a Sandebring-Matton, Anna $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden.
700    1_
$a Frykman, Susanne $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden.
700    1_
$a Tjernberg, Lars O $u Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden.
773    0_
$w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 9, č. 1 (2017), s. 57
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28764767 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180712092154 $b ABA008
999    __
$a ok $b bmc $g 1316901 $s 1021691
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 9 $c 1 $d 57 $e 20170801 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...